Chitosan nanoparticle encapsulated pentoxifylline improves renal protection and reduces oxidative stress in amikacin induced nephrotoxicity
Source abstract
Abstract
Abstract Amikacin (AMK)-induced nephrotoxicity remains a clinical challenge, necessitating innovative therapeutic strategies. This study developed pentoxifylline-loaded chitosan nanoparticles (PTX-CSNPs) to enhance PTX’s renoprotective effects while minimizing its side effects. PTX-CSNPs were synthesized via ionic gelation, exhibiting high entrapment efficiency (89.53%) and sustained release (87% at 48 h). Characterization revealed spherical nanoparticles (30-50 nm by TEM and 79.05 nm by DLS) with positive zeta potential (+ 32.77 mV), confirmed by FTIR and XRD analyses. In vitro, PTX-CSNPs demonstrated superior antioxidant (98.73% DPPH scavenging), anti-inflammatory (76.46% RBCs membrane stabilization), and anticoagulant activity compared to free PTX. In vivo, AMK-induced nephrotoxic rats treated with PTX-CSNPs showed normalization of renal function biomarkers (BUN, creatinine, uric acid) and oxidative stress markers (MDA, SOD, GSH), alongside reduced inflammatory markers levels outperforming free PTX or CSNPs alone. Histopathology revealed preserved glomerular and tubular architecture. The nanoformulation’s efficacy was attributed to chitosan-mediated targeted delivery and PTX’s anti-inflammatory/antioxidant synergy. These findings highlighted PTX-CSNPs as a promising nanotherapeutic for drug-induced kidney injury, offering enhanced bioavailability and reduced systemic toxicity. Graphical abstract
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Chemotherapy-induced organ toxicity mitigation · Acute Kidney Injury Research · Natural Compounds in Disease Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (92)
Show source-provided references
1. Ferguson MA, Vaidya VS, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology. 2008;245:182–93.10.1016/j.tox.2007.12.024 ↗
2. Finn W, Porter G. Urinary biomarkers and nephrotoxicity. Clinical Nephrotoxins. 2nd ed. 2003:621–655.10.1007/1-4020-2586-6_33 ↗
3. Nagai J, Takano M. Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs. Expert Opin Drug Metab Toxicol. 2010;6(10):1125–38.10.1517/17425255.2010.497140 ↗
4. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743–50.
5. Rached E, Hoffmann D, Blumbach K, Weber K, Dekant W, Mally A. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin A in vivo and in vitro. Toxicol Sci. 2008;103(2):371–81.10.1093/toxsci/kfn040 ↗
6. Serio A, Magalhães M, Blanchard JS, Connolly L, Aminoglycosides: Mechanisms of Action and Resistance. In: Mayers D, Sobel J, Ouellette M, Kaye K, Marchaim D (eds) Antimicrobial Drug Resistance. Springer, Cham, 2017. https://doi.org/10.1007/978-3-319-46718-4_14.10.1007/978-3-319-46718-4_14 ↗
7. Richardson R, Smart M, Tracey-White D, Webster AR, Moosajee M. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders. Exp Eye Res. 2017;155:24–37.10.1016/j.exer.2017.01.001 ↗
8. Houghton JL, Green KD, Chen W, Garneau-Tsodikova S. The future of aminoglycosides: the end or renaissance? ChemBioChem. 2010;11(7):880–902.10.1002/cbic.200900779 ↗
9. Gad GF, Mohamed HA, Ashour HM. Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt. PLoS ONE. 2011;6(2):e17224.10.1371/journal.pone.0017224 ↗
10. Radigan EA, Gilchrist NA, Miller MA. Management of aminoglycosides in the intensive care unit. J Intensive Care Med. 2010;25(6):327–42.10.1177/0885066610377968 ↗
11. Lee H, Sohn YM, Ko JY, Lee SY, Jhun BW, Park HY, et al. Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease. Int J Tuberc Lung Dis. 2017;21(7):818–24.10.5588/ijtld.16.0791 ↗
12. Sima M, Hartinger J, Cikankova T, Slanar O. Estimation of once-daily amikacin dose in critically ill adults. J Chemother. 2017;29(6):323–9.
13. Marsot A, Guilhaumou R, Riff C, Blin O. Amikacin in critically ill patients: a review of population pharmacokinetic studies. Clin Pharmacokinet. 2017;56(2):127–38.10.1007/s40262-016-0428-x ↗
14. Pacifici G, Marchini G. Clinical pharmacokinetics of amikacin in neonates. Int J Pediatr. 2017;5:4407–28.
15. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79(1):33–45.10.1038/ki.2010.337 ↗
16. Ali BH, Al Za’abi M, Blunden G, Nemmar A. Experimental gentamicin nephrotoxicity and agents that modify it: a mini-review of recent research. Basic Clin Pharmacol Toxicol. 2011;109(4):225–32.10.1111/j.1742-7843.2011.00728.x ↗
17. Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology. 1984;35(7):407–17.10.1177/000331978403500703 ↗
18. Aviado DM, Porter JM, Pentoxifylline. A new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4(6):297–307.10.1002/j.1875-9114.1984.tb03380.x ↗
19. Leporini C, Pisano A, Russo E, D’Arrigo G, de Sarro G, Coppolino G, et al. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis. Pharmacol Res. 2016;107:315–32.10.1016/j.phrs.2016.03.001 ↗
20. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110(2):192–8.
21. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990;172(1):391–4.10.1084/jem.172.1.391 ↗
22. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Müller GA. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transpl. 2000;15(10):1535–46.10.1093/ndt/15.10.1535 ↗
23. Dávila-Esqueda ME, Martínez-Morales F. Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat. Exp Diabesity Res. 2004;5(4):245–51.
24. Lin SL, Chiang WC, Chen YM, Lai CF, Tsai TJ, Hsieh BS. The renoprotective potential of pentoxifylline in chronic kidney disease. J Chin Med Assoc. 2005;68(3):99–105.10.1016/S1726-4901(09)70228-X ↗
25. McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: A meta-analysis. Am J Kidney Dis. 2008;52(3):454–63.10.1053/j.ajkd.2008.01.025 ↗
26. Shan D, Wu HM, Yuan QY, Li J, Zhou RL, Liu GJ. Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev. 2012;2:CD006800.
27. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15(7):1877–1882.10.1097/01.ASN.0000131523.17045.56 ↗
28. El Metwally R, El Wakeel L, El Sharkawy M, Elborolossy R. Pentoxifylline reno-protective and anti-inflammatory effects and potential role in anemia of chronic kidney disease. Arch Pharm Sci Ain Shams Univ. 2024;8(2):261–74.
29. Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P, et al. Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizons. J Clin Med. 2019;8(3):287.10.3390/jcm8030287 ↗
30. Annamaraju P, Patel P, Baradhi KM. Pentoxifylline. StatPearls. 2024.
31. Chen L, Gao Y, Liu M, Li Q, Han C, Zhao Y, et al. Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study). Trials. 2023;24:491.10.1186/s13063-023-07547-y ↗
32. Liang X, Wang Y, Zhao C, Cao Y. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: a network meta-analysis. PLoS ONE. 2022;17(11):e0275392.10.1371/journal.pone.0275392 ↗
33. Fang JH, Chen YC, Ho CH, Chen JY, Hsing CH, Liang FW, et al. The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment. Sci Rep. 2021;11(1):13521.10.1038/s41598-021-92753-4 ↗
34. Desai N, Rana D, Salave S, Gupta R, Patel P, Karunakaran B, et al. Chitosan: a potential biopolymer in drug delivery and biomedical applications. Pharmaceutics. 2023;15(4):1313.10.3390/pharmaceutics15041313 ↗
35. Stefanache A, Lungu II, Anton N, Damir D, Gutu C, Olaru I, et al. Chitosan nanoparticle-based drug delivery systems: advances, challenges, and future perspectives. Polymers. 2025;17(11):1453.10.3390/polym17111453 ↗
36. Zhang Q, Li Y, Wang S, Gu D, Zhang C, Xu S, et al. Chitosan-based oral nanoparticles as an efficient platform for kidney-targeted drug delivery in the treatment of renal fibrosis. Int J Biol Macromol. 2024;256(Pt 1):128315.10.1016/j.ijbiomac.2023.128315 ↗
37. Prabaharan M, Mano JF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv. 2005;12(1):41–57.10.1080/10717540590889781 ↗
38. Dehghani P, Akbari A, Saadatkish M, Varshosaz J, Kouhi M, Bodaghi M. Acceleration of wound healing in rats by modified lignocellulose based sponge containing pentoxifylline loaded lecithin/chitosan nanoparticles. Gels. 2022;8(10):658.10.3390/gels8100658 ↗
39. Lin HI, Chu SJ, Wang D, Feng NH. Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect. 2004;37(1):8–15.
40. Asvadi I, Hajipour B, Asvadi A, Asl NA, Roshangar L, Khodadadi A. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci. 2011;15(9):1003–9.
41. Brasileiro JL, Inoye CM, Aydos RD, Silva IS, Falcão GR, Marks G, et al. Ischemia and reperfusion of rat small intestine using pentoxyfilline and prostaglandin E1. Acta Cir Bras. 2013;28(11):767–73.10.1590/S0102-86502013001100004 ↗
42. Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 2017;9(4):53.10.3390/pharmaceutics9040053 ↗
43. Moreira VM, Leite JMS, Medeiros KA, Assis KMA, Borges JC, Santana LMB, et al. Pentoxifylline/chitosan films on wound healing: in vitro/in vivo evaluation. Pharmaceutics. 2023;15(4):122.10.3390/pharmaceutics15041122 ↗
44. Moustafa N, El-Latif MBA, Farid A. Amikacin toxicity revisited: pentoxifylline offers protection in high-risk treatment scenarios. AMB Express. 2025;15(1):153.10.1186/s13568-025-01949-8 ↗
45. Batoo AS, Hussain K, Singh R, Sultana M, Sharma N, Nabi B, et al. Biochemical and oxidative alterations induced by acute amikacin toxicity in albino Wistar rats. J Anim Res. 2018;8:407–10.10.30954/2277-940X.06.2018.11 ↗
46. Samy M, Abd El-Alim SH, Rabia AEG, Amin A, Ayoub MMH. Formulation, characterization and in vitro release study of 5-fluorouracil loaded chitosan nanoparticles. Int J Biol Macromol. 2020;156:783–91.10.1016/j.ijbiomac.2020.04.112 ↗
47. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Kumar MNVR. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res. 2006;23:184–95.10.1007/s11095-005-8418-y ↗
48. Nair RS, Morris A, Billa N, Leong CO. An evaluation of curcumin-encapsulated chitosan nanoparticles for transdermal delivery. AAPS PharmSciTech. 2019;20(2):69.10.1208/s12249-018-1279-6 ↗
49. Farid A, Hossam A, Waheed M, Safwat G. Synthesis of rice husk-loaded chitosan nanoparticles for treatment of amikacin-induced kidney injury in male rats. Int J Biol Macromol. 2025;312:144125.10.1016/j.ijbiomac.2025.144125 ↗
50. Tarek K, Safwat G, Farid A. Evaluation of the effect of grape seed extract-loaded chitosan nanoparticles on cryptosporidiosis in dexamethasone immunosuppressed male mice. Int J Biol Macromol. 2025;306(Pt 2):141513.10.1016/j.ijbiomac.2025.141513 ↗
51. Chen MC, Mi FL, Liao ZX, Hsiao CW, Sonaje K, Chung MF, et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev. 2013;65(6):865–79.10.1016/j.addr.2012.10.010 ↗
52. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems—a review (Part 1). Trop J Pharm Res. 2013;12:255-64.
53. Sadeghi AM, Dorkoosh FA, Avadi MR, Saadat P, Rafiee-Tehrani M, Junginger HE. Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods. Int J Pharm. 2008;355(1–2):299–306.10.1016/j.ijpharm.2007.11.052 ↗
54. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100(1):5–28.10.1016/j.jconrel.2004.08.010 ↗
55. Madian N, Mohamed N. Enhancement of the dynamic mechanical properties of chitosan thin films by crosslinking with greenly synthesized silver nanoparticles. J Mater Res Technol. 2020;9:12970–5.10.1016/j.jmrt.2020.09.028 ↗
56. Kumar S, Nagpal M, Nagpal K, Dhingra GA. Sustained release solid dispersions of pentoxyfylline: formulation and optimization. J Pharm Technol Res Manag. 2014;2(1):13–28.10.15415/jptrm.2014.21002 ↗
57. Liu Y, Liang Y, Yuhong J, Xin P, Han JL, Du Y, et al. Advances in nanotechnology for enhancing the solubility and bioavailability of poorly soluble drugs. Drug Des Devel Ther. 2024;18:1469–95.10.2147/DDDT.S447496 ↗
58. Blebea NM, Pușcașu C, Vlad RA, Hancu G. Chitosan-Based Gel Development: Extraction, Gelation Mechanisms, and Biomedical Applications. Gels. 2025;11(4):275.10.3390/gels11040275 ↗
59. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chem Rev. 2016;116(4):2602–63.10.1021/acs.chemrev.5b00346 ↗
60. Thompson MK, Tuma RF, Young WF. The effects of pentoxifylline on spinal cord blood flow after experimental spinal cord injury. J Assoc Acad Minor Phys. 1999;10(1):23–6.
61. Saeed A, Sabri N, Saleh M, Ahmed M. Immunomodulatory and Antioxidant Effects of Pentoxifylline and Other Therapeutic Agents in The Management of Myocardial Injury. Arch Pharm Sci Ain Shams Univ. 2023;7(2):440–56.
62. Di Santo MC, D’Antoni CL, Domínguez Rubio AP, Alaimo A, Pérez OE. Chitosan-tripolyphosphate nanoparticles designed to encapsulate polyphenolic compounds for biomedical and pharmaceutical applications—a review. Biomed Pharmacother. 2021;142:111970.10.1016/j.biopha.2021.111970 ↗
63. Deree J, Martins J, de Campos T, Putnam JG, Loomis WH, Wolf P, et al. Pentoxifylline attenuates lung injury and modulates transcription factor activity in hemorrhagic shock. J Surg Res. 2007;143(1):99–108.10.1016/j.jss.2007.03.083 ↗
64. Chavarría AP, Vázquez RRV, Cherit JGD, Bello HH, Suastegui HC, Moreno-Castañeda L, et al. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. Comput Struct Biotechnol J. 2021;19:1379–91.10.1016/j.csbj.2021.02.009 ↗
65. Jafernik K, Ładniak A, Blicharska E, Czarnek K, Ekiert H, Wiącek AE, et al. Chitosan-based nanoparticles as effective drug delivery systems—a review. Molecules. 2023;28(4):1963.10.3390/molecules28041963 ↗
66. Gheorghiță D, Moldovan H, Robu A, Bița AI, Grosu E, Antoniac A, et al. Chitosan-based biomaterials for hemostatic applications: a review of recent advances. Int J Mol Sci. 2023;24(13):10540.10.3390/ijms241310540 ↗
67. Dou T, Wang J, Han C, Shao X, Zhang J, Lu W. Cellular uptake and transport characteristics of chitosan modified nanoparticles in Caco-2 cell monolayers. Int J Biol Macromol. 2019;138:791–9.10.1016/j.ijbiomac.2019.07.168 ↗
68. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.10.1201/b14095 ↗
69. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
70. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905.10.3390/molecules26195905 ↗
71. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based nanoparticles. Heliyon. 2022;8(1):e08674.10.1016/j.heliyon.2021.e08674 ↗
72. Eğin S, Açıksarı K, Ercan G, Aydın AF, Üstyol EA, Eser M, et al. Effects of pentoxifylline on oxidative stress in rats with abdominal compartment syndrome model. Int J Surg Open. 2016;5:5–10.10.1016/j.ijso.2016.09.001 ↗
73. Sunil VR, Vayas KN, Cervelli JA, Malaviya R, Hall LR, Massa CB, et al. Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress, and inflammation. Exp Mol Pathol. 2014;97(1):89–98.10.1016/j.yexmp.2014.05.009 ↗
74. Dawoud SF, Al-Akra TM, Zedan AM. Hepatoprotective effects of chitosan and chitosan nanoparticles against biochemical, genetic, and histological disorders induced by the toxicity of emamectin benzoate. Rep Biochem Mol Biol. 2021;10(3):506–14.
75. da Pedretti SLC, de Rena CL, Orellano LAA, de Lazari MG, Campos PP, Nunes TA. Benefits of pentoxifylline for skin flap tissue repair in rats. Acta Cir Bras. 2020;35(1):e202000107.10.1590/s0102-865020200010000007 ↗
76. Hassan I, Dorjay K, Anwar P. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014;5(4):510–6.10.4103/2229-5178.142528 ↗
77. Dhulqarnain AO, Takzaree N, Hassanzadeh G, Tooli H, Malekzadeh M, Khanmohammadi N, et al. Pentoxifylline improves the survival of spermatogenic cells via oxidative stress suppression and upregulation of PI3K/AKT pathway in mouse model of testicular torsion-detorsion. Heliyon. 2021;7(3):e06868.10.1016/j.heliyon.2021.e06868 ↗
78. Ahmad M, Abu-Taweel GM, Aboshaiqah AE, Ajarem JS. The effects of quinacrine, proglumide, and pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of status epilepticus. Oxid Med Cell Longev. 2014;2014:630509.10.1155/2014/630509 ↗
79. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother. 2005;59(6):302–6.10.1016/j.biopha.2005.05.003 ↗
80. Dinckan A, Sahin E, Ogus M, Emek K, Gumuslu S. The effect of pentoxifylline on oxidative stress in CO2 pneumoperitoneum. Surg Endosc. 2009;23(3):534–8.10.1007/s00464-008-9856-5 ↗
81. Nesek-Adam V, Vnuk D, Rašić Ž, Rumenjak V, Kos J, Krstonijević Z. Comparison of the effects of low intra-abdominal pressure and pentoxifylline on oxidative stress during CO2 pneumoperitoneum in rabbits. Eur Surg Res. 2009;43(3):330–337.10.1159/000237747 ↗
82. Su S, Kang PM. Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials. 2020;10(4):656.10.3390/nano10040656 ↗
83. Abdul Khalil HPS, Saurabh CK, Adnan AS, Nurul Fazita MR, Syakir MI, Davoudpour Y, et al. A review on chitosan-cellulose blends and nanocellulose reinforced chitosan biocomposites: properties and their applications. Carbohydr Polym. 2016;150:216–26.10.1016/j.carbpol.2016.05.028 ↗
84. Ghassemi B, Nayeri FD, Hosseini R. The effects of chitosan nanoparticles on genes expression of artemisinin synthase in suspension culture of Artemisia annua L.: a comparative study. Biocatal Agric Biotechnol. 2021;9:190–203.
85. Borza DB. Glomerular basement membrane heparan sulfate in health and disease: a regulator of local complement activation. Matrix Biol. 2017;57–58:299–310.10.1016/j.matbio.2016.09.002 ↗
86. Huang Y, Wang J, Jiang K, Chung EJ. Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions. J Control Release. 2021;334:127–37.10.1016/j.jconrel.2021.04.016 ↗
87. Alallam B, Choukaife H, Seyam S, Lim V, Alfatama M. Advanced drug delivery systems for renal disorders. Gels. 2023;9(2):115.10.3390/gels9020115 ↗
88. Soodvilai S, Soodvila S, Sajomsang W, Rojanarata T, Patrojanasophon P, Opanasopit P. In vitro and in vivo evaluation of amphiphilic chitosan derivatives for inhibition of organic cation transport function. Key Eng Mater. 2020;859:45–50.10.4028/www.scientific.net/KEM.859.45 ↗
89. Liu GW, Pippin JW, Eng DG, Lv S, Shankland SJ, Pun SH. Nanoparticles exhibit greater accumulation in kidney glomeruli during experimental glomerular kidney disease. Physiol Rep. 2020;8(15):e14545.10.14814/phy2.14545 ↗
90. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Ren Physiol. 2004;286(3):F552–63.10.1152/ajprenal.00285.2002 ↗
91. Liu D, Shu G, Jin F, Qi J, Xu X, Du Y, et al. ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule. Sci Adv. 2020;6(41):eabb7422.10.1126/sciadv.abb7422 ↗
92. Rençber S, Gündoğdu E, Köksal Karayıldırım Ç, Başpınar Y. Preparation and characterization of mucoadhesive gels containing pentoxifylline-loaded nanoparticles for vaginal delivery of genital ulcer. Iran Polym J. 2021;30:569–582.10.1007/s13726-021-00913-0 ↗